We have compared mivacurium and succinylcholine in 27 paediatric patients with mild (Child's A) to moderate (Child's B) liver disease undergoing oesophagogastroduodenoscopy (OGD) and injection of oesophageal varices, with 10 healthy children receiving mivacurium for ENT procedures. With mivacurium 0.2 mg kg 91 , the severity of liver disease did not correlate with duration of block compared with controls (time from bolus to T1 25%, P:0.74; T1 25% to T4:T1 90.7, P:0.545). However, initial recovery (time to T1 25%, P:0.002) and overall recovery (bolus to T4:T190.7, P:0.004) from mivacuriuminduced neuromuscular block correlated inversely with pre-existing concentrations of plasma cholinesterase. Conditions for tracheal intubation at 2 min with mivacurium were comparable with conditions at 1 min with succinylcholine in the liver patients. (Br.
Children with moderate to severe liver disease are at risk of developing portal hypertension and oesophageal varices. To limit and prevent episodes of haematemesis necessitates regular oesophagogastroduodenoscopy (OGD) to monitor progress and, if necessary, inject varices with sclerosant. 1 To facilitate this procedure, general anaesthesia and neuromuscular block are used. As the procedure may only last a few minutes if no varices are found, succinylcholine has been the agent of choice in the absence of a nondepolarizing neuromuscular blocking drug of sufficiently short duration. 2 Mivacurium, a short-acting, non-depolarizing benzylisoquinoline neuromuscular blocking drug, is a potentially useful agent in this context. In particular, it has a higher ED 95 (0.1 mg kg 91 ), faster onset, shorter duration of action and more rapid spontaneous recovery in children than in adults. 3 This should make it an ideal agent for this procedure.
However, the short duration of action of mivacurium results primarily from its extensive metabolism by plasma (butyryl-or pseudo-) cholinesterase (PChE). PChE concentrations may be reduced markedly in adults with liver disease and thus interfere with the metabolism of mivacurium: there is a significant negative correlation between recovery variables from mivacurium and PChE activity. 4 The object of this study was to evaluate and compare ease of intubation, effective duration of neuromuscular block and spontaneous recovery after administration of mivacurium or succinylcholine to paediatric patients with liver disease requiring OGD. These variables were equated with the pre-existing clinical severity of the liver disease and the concentration of PChE. A control group of healthy children requiring intubation, and neuromuscular block were treated with mivacurium. Groups A and B were randomized prospectively to receive succinylcholine or mivacurium in a ratio of 1:1. All patients in the control group C received mivacurium. Anaesthesia was standardized in all cases. After induction of anaesthesia, an i.v. cannula was inserted and blood obtained for measurement of PChE concentrations and estimation of dibucaine number. Neuromuscular monitoring was then attached (Datex Relaxograph, Datex, Finland) and calibrated. The compound evoked potential of the adductor pollicis muscle was recorded after supramaximal stimulation of the ulnar nerve at a frequency of 2 Hz in a train-of-four mode every 12 s. After a 1-min control period, patients allocated randomly to group mivacurium were given a dose of 0. End-tidal carbon dioxide and isoflurane were maintained at 3.5-4.5% and 0.5-1%, respectively, in all patients.
Methods and results
The following measurements were made from the Datex Relaxograph: percentage block at time of intubation (1 min with succinylcholine, 2 min with mivacurium); time from completion of administration of the first bolus dose to 25% recovery of T1; time from 25% recovery of T1 to T4:T190.7 (mivacurium only); and time from administration of the bolus dose to T4:T1 90.7 (mivacurium only). Neuromuscular function was allowed to recover spontaneously in all patients.
All statistical significance tests were two-sided at the 5% level.
Mean age of the patients was 6.4 (range of 2.2-11) yr. There were no significant differences between groups.
Mean concentrations of PChE (normal range 600-1400 iu litre . Mean PChE concentration was significantly greater (P:0.05) in healthy children compared with the liver patients.
Grade of intubation with succinylcholine at 1 min and mivacurium at 2 min showed no significant differences in the specified comparisons. In the 16 patients who received succinylcholine, intubation conditions were 14 grade 1, one grade 2 and one grade 3. In the 21 patients who received mivacurium, intubation conditions were 20 grade 1 and one grade 4.
There were no significant differences between the controls (group C) and the mivacurium-treated patients (groups A and B) for: time (min:s) from bolus to T1 25% (group C, 10:48 (SD 2:54) vs group A, 9:50 (2:58) and group B, 12:44 (2:46) (P:0.74)) and T1 25% to T4:T190.7 (group C, 5:59 (1:22) vs group A, 6:28 (1:42) and group B, 8:18 (2:57) (P:0.545)). Thus there was no evidence of prolongation in the overall recovery of mivacurium between Child's A and B and the control group. Recovery was faster in both groups with succinylcholine: time (min:s) from bolus to T1 25% (group A, 7:48 (3:45) and group B, 8:31 (1:51) (P:0.007)) and time from T1 25% to T4/T190.7 (group A, 2:02 (3:00) and group B, 1:11 (1:11) (P::0.001)).
Correlations between recovery variables and baseline PChE concentrations were calculated for mivacurium patients. Figure 1 shows a scatterplot of the predicted time, expressed as natural log, from administration of the bolus dose to 25% recovery of T1 and PChE concentrations in the mivacurium patients. The estimated correlation coefficient of 90.81 (P:0.002) indicates that high baseline concentrations of PChE were associated with shorter recovery times. Similarly, time from bolus administration to T4:T190.7 and PChE concentrations produced a correlation coefficient of 90.80 (P:0.004). In contrast, the estimated correlation coefficients of 90.14 (P:0.725) and 90.21 (P:0.61) indicate no evidence of an association between PChE concentrations and time from 25% recovery to 75% recovery of T1 or time from 25% recovery to T4:T190.7.
Comment
In our study of 10 healthy adult patients and 25 patients with cirrhosis of the liver who received a bolus dose of mivacurium 0.15 mg kg
91
, we found that patients with hepatic cirrhosis may be sensitive to mivacurium, which could be explained, at least in part, by lower PChE activity. 7 Our study has shown that in children with liver disease undergoing OGD and possible injection of oesophageal varices, duration and recovery from neuromuscular block with mivacurium 0.2 mg kg 91 did not correlate with the pre-existing clinical severity of liver disease (Child's A or B). However, recovery significantly correlated inversely with pre-existing concentrations of PChE. Conditions for tracheal intubation at 2 min with mivacurium were comparable with conditions at 1 min with succinylcholine. This implies that mivacurium is a suitable neuromuscular blocking drug in this group of patients which may be used instead of succinylcholine. 
